Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Colorectal

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 37.5%High 4 · 50%

Tumour response · people with metastatic CRC

Chemotherapy + bevacizumab leads to higher overall tumour response compared with chemotherapy (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.72 [1.23, 2.43]
4 studies · 1723 participants
High

Tumour response · people with metastatic CRC

The review found no eligible studies for this question.

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tumour response · people with metastatic CRC

FOLFOX + targeted therapy probably leads to higher overall tumour response compared with FOLFOX (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 2.64 [1.71, 4.06]
1 study · 578 participants
Moderate

Tumour response · people with metastatic CRC

FOLFIRI + targeted therapy probably leads to higher overall tumour response compared with FOLFIRI (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 2.07 [1.31, 3.28]
6 studies · 3192 participants
Moderate

Tumour response · people with metastatic CRC

Modern chemotherapy regimens leads to higher overall tumour response compared with 5‐flourouracil (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 2.96 [1.66, 5.27]
3 studies · 866 participants
High

Tumour response · people with metastatic CRC

Irinotecan + targeted therapy leads to higher overall tumour response compared with irinotecan (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 3.38 [2.53, 4.52]
2 studies · 1758 participants
High

Tumour response · people with metastatic CRC

Irinotecan‐based regimens leads to higher overall tumour response compared with irinotecan (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 2.87 [2.1, 3.93]
6 studies · 2577 participants
High

Tumour response · people with metastatic CRC

Irinotecan + oxaliplatin probably leads to higher overall tumour response compared with irinotecan (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 2.98 [1.91, 4.64]
1 study · 627 participants
Moderate